Braeburn Pharmaceuticals Inc. is challenging the breadth of three-year marketing exclusivity awarded to Indivior PLC’s Sublocade (buprenorphine extended-release), which is blocking its Brixadi buprenorphine depot injection from coming to market in the US.
In a lawsuit filed against the US Food and Drug Administration April 9, Braeburn said the exclusivity awarded to Sublocade...





